Understand the source comparison
IGF-1 LR3 Safe According to Studies: Full Comparison
Animal models (rodent skeletal muscle studies) Accelerated muscle repair, increased satellite cell activation, enhanced protein synthesis Rodent metabolism differs from human; dosing not directly translatable; short study durations (typically 4–12 weeks) Low.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Animal models (rodent skeletal muscle studies)
- Accelerated muscle repair, increased satellite cell activation, enhanced protein synthesis
- Rodent metabolism differs from human; dosing not directly translatable; short study durations (typically 4–12 weeks)
- Low. Mechanism demonstrated but safety profile unknown in humans
- Demonstrates potential anabolic mechanism but cannot establish human safety
- In vitro cellular studies
- Improved glucose uptake in isolated muscle cells; bypassed IGFBP inhibition
- No systemic effects measured; no assessment of cardiovascular, renal, or hepatic impact
- Very low. Isolated cell behavior does not predict whole-organism response
- Shows receptor-level activity but provides no data on organ-level safety
- Observational case reports (anecdotal)
- Muscle hypertrophy reported; hypoglycemia and joint pain also reported as adverse effects
- No controls; no standardized dosing; self-reported outcomes; publication bias
- Extremely low. Anecdotal reports lack reproducibility and dosage verification
- Cannot be used to make safety claims; highlights potential adverse effects
- Native IGF-1 clinical trials (not LR3)
- Elevated IGF-1 associated with increased cancer risk in some observational studies; therapeutic IGF-1 used in growth disorders under strict medical oversight
- Native IGF-1 is regulated by IGFBPs; LR3 analog bypasses this regulation entirely
- Moderate. Suggests caution but LR3-specific data needed
- Raises concern but cannot be directly applied to LR3 safety profile
- FDA-approved peptide analogs (e.g., mecasermin)
- Native IGF-1 (mecasermin) approved for severe primary IGF-1 deficiency; adverse effects include hypoglycemia, tonsillar hypertrophy, intracranial hypertension
- Mecasermin is native IGF-1, not the LR3 analog; used under strict endocrinologist supervision with regular monitoring
- Low to moderate. Shows that even native IGF-1 requires careful medical management
- Demonstrates that IGF-1 signaling carries inherent risks even in approved contexts